Go Pro
→ Elon Musk’s Hushed FCC Filing. Sept 25th. (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$266.05
+0.1%		$258.08
$173.33
▼
$276.47
$641.15B0.248.17 million shs2.60 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.94
-1.2%		$8.47
$6.20
▼
$11.97
$1.47B2.464.66 million shs1.40 million shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.60%-0.73%-0.25%+18.18%+50.60%
Novavax, Inc. stock logo
NVAX
Novavax
-1.74%+7.48%+22.80%-17.50%+19.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$266.05
+0.1%		$258.08
$173.33
▼
$276.47
$641.15B0.248.17 million shs2.60 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$8.94
-1.2%		$8.47
$6.20
▼
$11.97
$1.47B2.464.66 million shs1.40 million shs
10 Best Stocks to Own - Summer 2026 Cover
10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.60%-0.73%-0.25%+18.18%+50.60%
Novavax, Inc. stock logo
NVAX
Novavax
-1.74%+7.48%+22.80%-17.50%+19.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.80
Moderate Buy$268.220.81% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0056.60% Upside

Current Analyst Ratings Breakdown

Latest NVAX and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$270.00 ➝ $287.00
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/4/2026
Novavax, Inc. stock logo
NVAX
Novavax
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
8/3/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$280.00
8/3/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Johnson Rice logo
Johnson Rice
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/3/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$272.00 ➝ $282.00
7/29/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$300.00
7/24/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
7/17/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$270.00
7/16/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Johnson Rice logo
Johnson Rice
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Buy$280.00
7/16/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$305.00
(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$97.93B6.55$13.91 per share19.12$35.26 per share7.55
Novavax, Inc. stock logo
NVAX
Novavax
$413.80M3.56$3.41 per share2.62($1.16) per share-7.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6330.8320.792.5821.48%32.42%13.35%10/13/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)

Latest NVAX and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
7/15/2026Q2 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.84$2.90+$0.06$2.27$25.06 billion$25.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.362.01%+5.25%62.11%64 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest NVAX and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.341.96%8/25/20268/25/20269/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.09
0.81
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.41 billionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable

Recent News About These Companies

Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/novavaxs-partnership-strategy-continues-to-deliver-with-xfg-adapted-nuvaxovid-approvals-in-the-us-eu-and-japan-for-2026-2027-vaccination-season-302862775.html
Zacks Research Has Negative Outlook for Novavax Q3 Earnings
August 28 at 7:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-has-negative-outlook-for-novavax-q3-earnings-2026-08-28/
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
August 27 at 7:11 PM  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/08/61484141/quick-spark-fda-approves-updated-covid-vaccines-from-moderna-pfizer-novavax
US FDA approves updated COVID vaccines for 2026-27 season
August 27 at 5:48 PM  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-updated-covid-vaccines-2026-27-season-2026-08-27/
Ambros Therapeutics Announces Appointments of John C. Jacobs and Scott Robertson to Board of Directors
August 27 at 12:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/ambros-therapeutics-announces-appointments-john-123500490.html
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
August 26 at 3:16 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/unpacking-q2-earnings-novavax-nasdaq-141913447.html
Novavax Stock Pulls Back After Milestone Vaccine Success
August 26 at 3:16 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-stock-pulls-back-milestone-184821471.html
Novavax Stock Pulls Back After Milestone Vaccine Success
August 26 at 2:48 PM  |  schaeffersresearch.comhttps://www.schaeffersresearch.com/content/analysis/2026/08/26/novavax-stock-pulls-back-after-milestone-vaccine-success
Traders Purchase Large Volume of Put Options on Novavax (NASDAQ:NVAX)
August 26 at 2:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-traders-purchase-large-volume-of-put-options-on-novavax-nasdaq-nvax-2026-08-26/
Novavax stock rallies Tuesday: What's happening?
August 26 at 4:52 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/novavax-stock-rallies-tuesday-what-s-happening/ar-AA2aUphq
Novavax Stock Rallies Tuesday: What's Happening?
August 25 at 11:51 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/08/61413450/novavax-stock-rallies-tuesday-whats-happening
Novavax (NASDAQ:NVAX) Trading Up 6.9% - Still a Buy?
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-trading-up-69-still-a-buy-2026-08-21/
Stock Traders Purchase Large Volume of Novavax Call Options (NASDAQ:NVAX)
August 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973150
Novavax stock moves higher Wednesday: What's driving the action?
August 20, 2026  |  msn.comhttps://www.msn.com/en-us/money/news/novavax-stock-moves-higher-wednesday-whats-driving-the-action/ar-AA2auLU4
Novavax (NASDAQ:NVAX) Stock Price Down 6.8% - What's Next?
August 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novavax-nasdaqnvax-stock-price-down-68-whats-next-2026-08-20/
Recursion, Novavax and CRISPR stocks trending in pre-market—here's why
August 20, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/recursion-novavax-and-crispr-stocks-trending-in-pre-market-here-s-why/ar-AA2ay4BP
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
August 20, 2026  |  benzinga.comhttps://www.benzinga.com/markets/equities/26/08/61322461/recursion-novavax-crispr-stocks-premarket-cancer-therapy-rally
BioNTech Stock Surges 22% on Moderna Cancer Vaccine Win. Why the Gains Could Fade.
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/m/54926def-c88c-3783-9c11-a0a6c00b7bed/biontech-stock-surges-22%25-on.html
Novavax (NVAX) Shares Skyrocket, What You Need To Know
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-nvax-shares-skyrocket-know-215002669.html
How Moderna’s Cancer Breakthrough Reversed Its Fortunes and Revived the Stock
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/m/46ee6bad-a1ca-3803-901e-a9bb055a64e6/how-moderna%E2%80%99s-cancer.html
Investors Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)
August 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/investors-buy-large-volume-of-call-options-on-novavax-nasdaqnvax-2026-08-19/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$266.05 +0.28 (+0.11%)
As of 12:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novavax stock logo

Novavax NASDAQ:NVAX

$8.94 -0.11 (-1.22%)
As of 12:57 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas